Bayer/Algeta $800M licensing deal for a late stage cancer drug: <a href="http://www.reuters.com/article/rbssHealthcareNews/idUSL358283220090903" rel="nofollow" target="_blank">http://www.reuters.com/article/rbssHealthcareNews/idUSL358283220090903</a>